摘要
目的研究多肿瘤标志物蛋白芯片诊断系统用于筛查早期肿瘤及疗效监测的价值。方法用多肿瘤标志物蛋白芯片诊断系统测定分析282例健康体检人群,185例临床确诊的各种肿瘤患者和136例肿瘤术后监测患者的12种常见的肿瘤标志物甲胎蛋白(AFP),癌胚抗原(CEA),神经元特异性烯醇化酶(NSE),糖原125(CA125),糖原153(CA153),糖原242(CA242),糖原199(CA199),前列腺特异性抗原(PSA),游离前列腺特异性抗原(f-PSA),铁蛋白(FER),β-人绒毛膜促性腺激素(β-HCG),人生长激素(HGH)。结果被检测282例健康体检者中,超出参考值范围的结果有2例,后经随访均证实确诊为早期肿瘤患者(阳性率为0.71%);185例临床确诊的恶性肿瘤患者中,153例结果异常(阳性率为82.70%);另有136例为术后监测,125例结果正常,11例结果异常。结论多肿瘤标志物蛋白芯片诊断系统对于肿瘤筛查、监测其复发和转移均有较好的应用价值。
Objective To evaluate the multi-tumor markers system on screening earlier tumor and monitoring therapies by protein biochip technology.~Methods Using the multi-tumor markers protein biochip diagnostic system to determine and analyze the concentration values of 12 tumor markers (AFP, CEA, NSE, CA125, CA153, CA242, CA199, PSA, f-PSA, FER, β-HCG and HGH) from control group of 282 healthy people, 185 cases of clinical detected cancer patients at different clinical stages, and 136 detected cancer patients under post-operation monitoring.~Results 2 abnormal results beyond reference ranges were found in 282 healthy controls, which were finally diagnosed earlier period tumor by follow-up survey(positive ratio was 0.71%),153 out of 185 cancer patients at different clinical stages were abnormal (positive ratio was 82.70%),in addition, there were 11 abnormal results l in 136 detected cancer patients under post-operation monitoring.Conclusion The multi-tumor markers protein biochip diagnostic system may take a significant role in screeing tumor and observing recurrence and metastasis.
出处
《公共卫生与预防医学》
2005年第3期27-29,共3页
Journal of Public Health and Preventive Medicine
